93 filings
Page 3 of 5
S-1MEF
bd7ssyyfq 6u59
6 Oct 22
Registration of additional securities for an S-1
9:20pm
CORRESP
05udxg8u7le8t0thx5s
4 Oct 22
Correspondence with SEC
12:00am
CORRESP
3lw6e9sunayjz
4 Oct 22
Correspondence with SEC
12:00am
8-K
4mthoy3nfbj 6zxz
30 Sep 22
Amylyx Pharmaceuticals Announces FDA Approval of RELYVRIO™ for the Treatment of ALS
7:48am
UPLOAD
ui6ejce
31 Aug 22
Letter from SEC
12:00am
DRS
svdmyxno5 sces8
24 Aug 22
Draft registration statement
12:00am
8-K
phc74 l5kezv0r2lkhc2
11 Aug 22
Amylyx Pharmaceuticals Reports Second Quarter 2022 Financial Results
5:30pm
8-K
610vvh ao
11 Aug 22
Amylyx Pharmaceuticals Reports Second Quarter 2022 Financial Results
4:13pm
8-K
215v3w
5 Jul 22
Amylyx Pharmaceuticals Announces FDA Plan to Reconvene Advisory Committee to Review AMX0035
5:18pm
8-K
5qey8
13 Jun 22
Amylyx Pharmaceuticals Announces Health Canada Approval of ALBRIOZA™ for the Treatment of ALS
7:16am
8-K
wtmtlu
9 Jun 22
Submission of Matters to a Vote of Security Holders
4:02pm
8-K
emaab2mm3udyda
3 Jun 22
Amylyx Pharmaceuticals Receives Notification of PDUFA Date Extension for AMX0035 for the Treatment of ALS
7:27am
10-Q
c61hr dol8
12 May 22
Quarterly report
4:26pm
8-K
6n9bk avoyy6y4vt
12 May 22
Amylyx Pharmaceuticals Reports First Quarter 2022 Financial Results
4:14pm
DEFA14A
i49yz
29 Apr 22
Additional proxy soliciting materials
7:06am
DEF 14A
rsdn im2rgok71l
29 Apr 22
Definitive proxy
7:04am
10-K
eugy7in3xb4ag5t6nju
31 Mar 22
Annual report
2:23pm
8-K
c47fuajkt5rax7r jbq
30 Mar 22
Amylyx Pharmaceuticals Reports Full Year 2021 Financial Results
8:28pm